Merck's Keytruda U.S. Lung Cancer Nod: Broad Enough?
This article was originally published in Scrip
When Merck & Co. Inc. won FDA approval on Oct. 2 of its programmed death-1 (PD-1) immune checkpoint inhibitor Keytruda (pembrolizumab) in non-small-cell lung cancer (NSCLC) – the drug's second U.S. approval, gaining an earlier nod in melanoma – investors may have been hoping for a broader indication.
Register for our free email digests: